Back to News
Jun 18, 2026 8:10 AM

COUR Pharma Announces Closing of $50 Million Series B

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today it has closed a $50 million Series B funding round led by existing investors Lumira Ventures and Roche Venture Fund with participation from new investor, Sanofi. Existing investors including Alpha Wave Ventures, Pfizer Ventures, Angelini Ventures, and T1D Fund: A Breakthrough T1D Venture also participated, demonstrating continued conviction in COUR's tolerance platform.

The proceeds will be used to support the clinical advancement of CNP-103, an investigational therapy developed using COUR's proprietary nanoparticle platform for antigen-specific immune tolerance. CNP-103 is being evaluated in an active Phase 2 randomized, double-blind, placebo-controlled trial (NCT06783309) to assess its safety, tolerability, pharmacodynamics, and efficacy in adolescents and adults ages 12-35 who have been ...